[Form 4] Arteris, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Arteris, Inc. (AIP) – Form 4 Insider Transaction

Director S. Atiq Raza, acting through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold 19,809 shares of Arteris common stock on 27 June 2025 under a pre-arranged Rule 10b5-1 trading plan adopted on 6 June 2024. The weighted-average sale price was $10.02 per share (individual trade prices ranged from $10.00 to $10.10).

Following the transaction, the trust continues to hold 683,798 shares, leaving Mr. Raza with a substantial ownership position. The filing states that the trade was reported on 1 July 2025 and was executed indirectly through the trust.

• Form type: SEC Form 4
• Insider role: Director
• Nature of trade: Open-market sale (code “S”)
• Approximate transaction value: $199,000

The relatively small percentage of shares sold (≈2.8 % of the insider’s reported holdings) and the existence of a 10b5-1 plan mitigate potential negative signalling, yet investors often monitor insider sales for sentiment clues.

Positive

• Sale executed under a Rule 10b5-1 plan, reducing concerns about opportunistic trading and signalling adherence to governance best practices.
• Director still holds 683,798 shares, preserving substantial insider alignment with shareholders.

Negative

• Insider sale of 19,809 shares may be interpreted by some investors as a cautious sentiment signal, even if modest in size.

Insights

Securities Analyst

TL;DR: Modest 20k-share 10b5-1 sale; ownership still high, neutral signal.

The disposition represents about 2.8 % of Mr. Raza’s 703,600 pre-sale shares, raising roughly $0.2 million. Because the transaction was executed under a previously adopted 10b5-1 plan, it is less likely to indicate a short-term view on fundamentals. Post-sale ownership of 683,798 shares remains material, aligning director incentives with shareholders. From a valuation standpoint, the sale is immaterial to market cap and does not alter free-float dynamics meaningfully. I view the disclosure as neutral for the equity.

Corporate Governance Expert

TL;DR: Pre-planned sale limits governance concern; monitor future activity.

Insider sales can raise red flags, but the affirmative 10b5-1 disclosure satisfies best-practice transparency standards. The weighted-average pricing disclosure and willingness to provide granular trade data on request further support governance quality. The director retains a sizeable stake, maintaining alignment. Unless a pattern of accelerated selling emerges, the event is not materially negative for shareholder oversight.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAZA SAIYED ATIQ

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2025		S(1)		19,809	D	$10.0203(2)	683,798	I	Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012(3)
Common Stock								20,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 6, 2024.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.10 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for S. Atiq Raza	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Arteris (AIP) shares did Director S. Atiq Raza sell?

He sold 19,809 shares of common stock on 27 June 2025.

What was the average price of the shares sold by the Arteris insider?

The weighted-average sale price was $10.02, with trades ranging from $10.00 to $10.10.

Does the insider sale follow a 10b5-1 trading plan?

Yes. The filing states the transaction was made under a Rule 10b5-1 plan adopted on 6 June 2024.

How many Arteris shares does the insider still own after the sale?

After the sale, the trust controlled by the insider owns 683,798 shares.

Is the insider still classified as a director at Arteris (AIP)?

Yes. Box 5 of the Form 4 confirms Mr. Raza’s continuing role as a Director.